Distance from Distal Great Saphenous Vein to Saphenofemoral Junction
The distal great saphenous vein (GSV) is located at the ankle, approximately 24.4 mm anterior to the medial malleolus, while the saphenofemoral junction (SFJ) sits in the groin approximately 2.4 cm lateral and 1 cm inferior to the pubic tubercle 1, 2. The total distance between these two anatomic landmarks spans the entire length of the lower extremity—typically 70-90 cm in adults—making "distal GSV" and "saphenofemoral junction" opposite ends of the same venous structure.
Anatomic Landmarks
Distal GSV (Ankle Level)
- Located 24.4 ± 7.9 mm anterior to the most prominent point of the medial malleolus 2
- Mean collapsed diameter of 3.8 ± 1.5 mm at the ankle 2
- Mean depth from skin surface of 4.1 ± 1.2 mm 2
Saphenofemoral Junction (Groin)
- Center lies 2.4 ± 0.6 cm lateral to the pubic tubercle (range 1-4.5 cm) 1
- Positioned 1 ± 0.9 cm inferior to the pubic tubercle (range 2.5 cm above to 4 cm below) 1
- In men: 2.6 cm lateral and 1.2 cm inferior; in women: 2.2 cm lateral and 0.6 cm inferior 1
- Junction is inferior to the pubic tubercle in 90% of limbs 1
Clinical Relevance in Cancer Patients on Megestrol Acetate
For your cancer patient taking megestrol acetate, the critical clinical question is not the total GSV length but rather the proximity of any superficial vein thrombosis (SVT) to the saphenofemoral junction, as this determines anticoagulation intensity 3, 4.
Thrombosis Risk Stratification by Distance from SFJ
Therapeutic-dose anticoagulation for at least 3 months is mandatory when GSV thrombus lies within 3 cm of the saphenofemoral junction due to high risk of propagation into the deep venous system 3, 4.
Prophylactic-dose anticoagulation for at least 6 weeks is indicated when:
Surveillance ultrasound in 7-10 days with anticoagulation only if progression occurs when:
Cancer-Specific Considerations
Megestrol acetate is prescribed for palliative treatment of advanced breast or endometrial carcinoma 5, and while one large database study found no statistically significant increase in venous thromboembolism (VTE) risk with megestrol acetate in metastatic gastric cancer patients 6, active malignancy itself substantially elevates baseline VTE risk 4.
Low-molecular-weight heparin (LMWH) is the preferred therapeutic anticoagulant in active cancer 4, with direct oral anticoagulants (DOACs) as an acceptable alternative 4.
For prophylactic dosing, rivaroxaban 10 mg orally daily or fondaparinux 2.5 mg subcutaneously daily are effective options 3, 4.
Common Pitfalls
The 3 cm threshold from the SFJ is the critical decision point—not the total GSV length 3, 4. Research demonstrates that GSV thrombus within 5 cm of the SFJ carries significantly higher pulmonary embolism risk (all 7 PE cases occurred in this group, P=0.02) 7, reinforcing the guideline's conservative 3 cm cutoff.
Catheter tip positioning during endovenous procedures averages 2.75 cm from the SFJ 8, which provides context for understanding the anatomic proximity that defines high-risk thrombus location.